Nucleos(t)ide Analogue
AB-729 + Pegylated Interferon for Chronic Hepatitis B
This trial is testing a new drug called AB-729 for patients with Chronic Hepatitis B. It is used along with existing treatments to lower virus levels, manage the virus, and boost the immune system.
Antiviral
JNJ-73763989 + Antivirals for Hepatitis B and D Co-Infection
This trial is testing a new drug called JNJ-73763989 combined with an existing medication to treat hepatitis D virus (HDV). The goal is to see if this combination works better than the current treatment alone. The new drug is expected to enhance the effectiveness of the existing medication.
Popular Filters
Trials for HBV Patients
TLR8 Agonist
Selgantolimod for Chronic Hepatitis B and HIV
This trial tests a pill called Selgantolimod in patients with chronic hepatitis B and HIV who have been on antiviral therapy for an extended period. The pill aims to activate the immune system to reduce the hepatitis B virus levels in their blood.
Trials for Chronic Hepatitis B Patients
Antisense Oligonucleotide
Daplusiran/Tomligisiran + Bepirovirsen for Chronic Hepatitis B
This trial aims to test the effectiveness and safety of two different doses of a drug combination (DAP/TOM) followed by another drug (bepirovirsen) in people with chronic hepatitis B
Virus Therapy
VIR-2218 + VIR-3434 + PEG-IFNα for Chronic Hepatitis B
This trial involves testing three treatments (VIR-2218, VIR-3434, and PEG-IFNα) on patients with chronic hepatitis B. The goal is to see if these treatments are safe, can be tolerated by patients, and are effective in reducing the virus. The treatments work by either lowering the virus levels or boosting the immune system to fight the virus. Peginterferon alpha (PEG-IFNα) has been used to treat chronic hepatitis B by modulating the immune system, often in combination with other medications for enhanced efficacy.
Nucleoside Reverse Transcriptase Inhibitor
TAF for Chronic Hepatitis B
This trial is testing a new drug, tenofovir alafenamide, to see if it is safe and effective in treating children and adolescents with chronic hepatitis B. The trial will consist of two parts, with the first part focused on collecting information about the new drug's pharmacokinetics in children, and the second part testing the safety and efficacy of the drug in children with chronic hepatitis B.
NA therapy
Stopping Antiviral Therapy for Chronic Hepatitis B
This trial is for patients with the early antigen negative form of chronic hepatitis B who have been on antiviral drugs for at least 192 weeks. The trial offers the option to stop or continue treatment to see if there are any clinical differences and what the mechanisms and gene expression profiles are that correlate with the clinical course.
Trials With No Placebo
Chemotherapy
MTL-CEBPA + Sorafenib for Liver Cancer
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Rapid Screening for Hepatitis C & B
This trial aims to study the effectiveness of rapid screening methods in diagnosing viral hepatitis infections compared to traditional methods. The goal is to provide same-day results to improve diagnosis rates and help healthcare providers engage with
View More Related Trials
Frequently Asked Questions
Introduction to hepatitis b
What are the top hospitals conducting hepatitis b research?
In the ongoing fight against hepatitis b, several top hospitals are at the forefront of groundbreaking clinical trials. One such institution is the University of California, San Francisco (UCSF) located in vibrant San Francisco. UCSF currently has three active trials dedicated to hepatitis B, with a cumulative total of seven trials conducted over time. Their pioneering efforts began back in 1999 when they recorded their first trial for this condition.
Moving eastward to Aurora, Colorado, we find the University of Colorado Hospital CRS making significant contributions to hepatitis B research. With two active trials and a small but impactful history of three previous studies on this disease, this hospital continues to push boundaries since embarking on their first hepatitis B trial just last year in 2020.
Meanwhile, across the country in Washington D.C., Whitman-Walker Health CRS is also actively involved in fighting against hepatitis B with two ongoing clinical trials. Their commitment began recently as well when they initiated their first recorded trial for this condition alongside The Ponce de Leon Center CRS based in Atlanta and Northwestern University CRS located within Chicago both showcasing similar dedication by conducting hepatisisb related research through two active projects while having participation experience before once again since entering into field coincidingly only from 2020 onwards.
These hospitals play vital roles not only by offering hope to those affected by hepatitis B but also by pushing forward our understanding and treatment options for this serious liver infection that affects millions worldwide. Through these clinical trials conducted across various locations throughout the United States - from sunny San Francisco all the way to bustling Chicago - medical professionals are working diligently towards finding new treatments and ultimately striving for better outcomes for patients living with hepatitis B
Which are the best cities for hepatitis b clinical trials?
When it comes to hepatitis b clinical trials, several cities stand out as hubs for cutting-edge research. In New york, there are currently 17 active trials exploring treatments like Selgantolimod and HEPLISAV-B among others. San Francisco follows closely behind with 12 ongoing studies that investigate interventions such as stopping NA therapy and utilizing Selgantolimod. Honolulu in Hawaii also boasts 12 active trials focusing on Tenofovir Alafenamide and other potential breakthroughs. Lastly, Los Angeles and Houston both contribute to the advancement of hepatitis B research with their respective nine and eight active trials studying various treatment options. Through these dedicated efforts in multiple cities across the United States, researchers strive to improve outcomes for individuals affected by hepatitis B infection.
Which are the top treatments for hepatitis b being explored in clinical trials?
Exciting advancements are underway in the clinical trials exploring treatments for hepatitis b. Among the top contenders is GSK3228836, currently being tested in two active trials and with a total of six all-time hepatitis B trials since its introduction in 2020. Another promising option is JNJ-73763989, which has also gained traction with two ongoing trials and nine all-time hepatitis B studies since it was first listed in 2019. Additionally, Tenofovir Alafenamide shows promise as a treatment option with two active trials and an impressive tally of 18 all-time hepatitis B trials dating back to 2010. Lastly, keep an eye on bepirovirsen, a newcomer to the scene that has already initiated two active clinical trials after its listing in 2022. As research progresses further into these various investigational treatments, hope continues to grow for patients affected by hepatitis B worldwide.
What are the most recent clinical trials for hepatitis b?
Exciting developments in the field of hepatitis b research have brought forth promising clinical trials that may pave the way for improved treatment options. One such trial is Active, a Phase 2 study that aims to assess the efficacy and safety of a new intervention for hepatitis B. Additionally, Group 1a investigates the potential benefits of HepB mAb19 administered intravenously, with Phase 1 focusing on determining its safety profile. Another noteworthy trial is Selgantolimod, currently in Phase 2, which holds promise as a potential therapeutic agent against hepatitis B. The development and evaluation of these innovative treatments signify significant progress towards addressing this challenging condition and improving patient outcomes.
What hepatitis b clinical trials were recently completed?
Recently, several important clinical trials investigating potential treatments for hepatitis b have reached completion. In September 2021, GlaxoSmithKline concluded a trial studying the effectiveness of GSK3228836. Additionally, Nucorion Pharmaceuticals wrapped up their investigation into NCO-48 Fumarate 20 mg in January 2021. Another trial involving GSK3228836 by GlaxoSmithKline was completed in July 2020. Furthermore, Janssen Sciences Ireland UC completed their study on JNJ-73763989 back in August 2019. Finally, the University of Maryland conducted a trial exploring the benefits of B/F/TAF that finished in April 2019. These recent advancements mark significant progress towards improving treatments for hepatitis B and offer hope to those affected by this persistent virus.